The latest update is out from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ).
Hansoh Pharmaceutical Group Company Limited has announced that its self-developed B7-H3-targeted antibody-drug conjugate, HS-20093, has been granted Breakthrough-Therapy-Designated status by the National Medical Products Administration of China for the treatment of non-squamous non-small cell lung cancer. This designation highlights the potential impact of HS-20093 on the company’s operations and industry positioning, as it progresses through multiple clinical trials, including Phase III, for various cancer treatments.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative drugs. The company is involved in creating treatments for various cancers and other solid tumors, with a strong emphasis on antibody-drug conjugates.
YTD Price Performance: 26.45%
Average Trading Volume: 9,842,283
Technical Sentiment Signal: Sell
Current Market Cap: HK$131.5B
For an in-depth examination of 3692 stock, go to TipRanks’ Stock Analysis page.